InvestSMART

Patrys Limited (ASX: PAB) - Share Price

Current share price for PAB : $0.040 0.001 (2.44%)+

Patrys Limited (PAB), an ASX-listed company, is a Company that is engaged in developing novel antibody technologies for cancer and NETosis-driven inflammatory diseases.

PAB General Information +

ASX Code PAB
Website http://www.patrys.com
Industry/Sector Biotechnology
Market Cap ($M) 26
PAB Share Price $0.040
Day High $0.041
Day Low $0.040
Last Close $0.041
PAB Share Price Movement $0.00 ( 2.44% )
Prices as at 15:26, 26 Jun 2026
+Security prices are delayed by at least 20 minutes and are indicative only.

Patrys Limited (PAB) Upcoming Dividends & Yields

Distribution Type Dividend Franking Ex-dividend date Payment date Current Price+ Price 7D Avg Dividend Yield

See all dividends from Patrys Limited (PAB) or use our Upcoming Dividends tool to search for dividends across all ASX-listed securities.

Patrys Limited (PAB) price-sensitive announcements

PAB - Patrys advances RLS-2202 toward Phase 1 Clinical Trial
Patrys Limited has advanced its RLS-2202 program towards a Phase 1A clinical trial by appo
Patrys Limited (PAB)
20 May 2026 | 9:31 AM
PAB - Appendix 4C - Quarterly - 31 March 2026
Patrys Limited has positioned itself for a clinical transition as it advances its lead pro
Patrys Limited (PAB)
30 Apr 2026 | 9:13 AM
PAB - $3.2 million Placement to Advance Clinical Trials
Patrys Limited has successfully raised A$3.2 million through a placement of approximately
Patrys Limited (PAB)
20 Apr 2026 | 9:31 AM
PAB - Trading Halt
On 16 April 2026, Patrys Limited requested a trading halt for its securities on the ASX, p
Patrys Limited (PAB)
16 Apr 2026 | 8:53 AM

Patrys Limited (PAB) Recent ASX Announcements

Company Sector Market Cap ($m) Headline Release
date/time+		 Price at
release+		 Current
price+		 Gain/Loss View
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Proposed issue of securities - PAB 9 Jun 2026 8:28AM $0.042 $0.040 fallen by 4.76%
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Results of Meeting 9 Jun 2026 8:26AM $0.042 $0.040 fallen by 4.76%
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Patrys advances RLS-2202 toward Phase 1 Clinical Trial 20 May 2026 9:31AM $0.032 $0.040 risen by 25%
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Appendix 4C - Quarterly - 31 March 2026 - Updated 15 May 2026 6:20PM $0.031 $0.040 risen by 29.03%
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Letter to Shareholders - General Meeting 6 May 2026 8:17AM $0.029 $0.040 risen by 37.93%
Patrys Limited (PAB)
ORDINARY FULLY PAID
 Health Care $27 Notice of General Meeting/Proxy Form 6 May 2026 8:17AM $0.029 $0.040 risen by 37.93%

PAB Financial Summary

Year to Jun NPAT EPS EPS chg (%) PER DPS Yield (%) Franking (%)
2025A -$2.71 -$1.40 -23.50% 0.00 0.00 0.00% 0.0%
2024A -$3.54 -$1.80 -50.00% 0.00 0.00 0.00% 0.0%
2023A -$7.06 -$3.70 -0.50% 0.00 0.00 0.00% 0.0%

PAB Peer Comparison

Company Mkt Cap EPS Growth (%) P/E (%) Dividend Yield (%)
2023 A 2024 A 2025 A 2023 A 2024 A 2025 A 2023 A 2024 A 2025 A
CSL Limited (CSL) $55,070M 0.1108 -0.1307 0.0166 12.3304 14.1849 13.9537 3.88% 3.13% 3.26%
Clinuvel Pharmaceuticals Limited (CUV) $514M 0.0287 0.0233 0.0942 14.2061 13.8832 12.6881 0.49% 0.71% 1.15%
Mesoblast Limited (MSB) $2,887M 0.0301 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Patrys Limited (PAB) $27M -0.2350 0.0000 0.0000 0.0000 0.0000 0.0000 0.00% 0.00% 0.00%
Telix Pharmaceuticals Limited (TLX) $5,338M -1.3893 0.0000 -0.1306 0.0000 293.4701 337.5536 0.00% 0.00% 0.00%

PAB Market Comparison

Earnings P/E Ratio P/B Ratio P/E Growth
Company 0.00 0.00 12.40 0.00
Market 0.29 13.30 1.15 0.61
Sector 0.43 26.10 2.44 2.36

PAB Directors

Name Position Start Date
Mr Peter James Christie Non-Executive Chairman, Non-Executive Director 17 Jun 2025
Mr Brian Willoughby Leedman Non-Executive Director 10 Nov 2025
Dr Anton Uvarov Non-Executive Director 17 Jun 2025
Ms Leanne Kite Non-Executive Director 28 Jan 2026
Mr Dino Cercarelli Non-Executive Director 28 Jan 2026

Patrys Limited (PAB) Changes in Directors' Interest & Trades

Date of change Director Buy/Sell Security Type Qty Trade Price Value
10 Feb 2026 LEEDMAN, Brian Transfer Direct Shares 2,000,000 $0.015 $30,000.000
22 Oct 2025 CAMPBELL, James Issued Direct Shares 10,701,795 $0.015 $160,526.925
22 Oct 2025 UVAROV, Anton Issued Direct Shares 3,333,333 $0.015 $50,000.000

See all changes in directors' interest & trades for Patrys Limited (PAB) or use our Changes in directors' interest tool to search for changes & trades across all ASX-listed securities.

PAB Management

Name Position
Johnathon Busing Joint Company Secretary
Kieran Witt Joint Company Secretary

PAB Substantial Shareholders

Under ASX rules large investors and investment funds must disclose when they own more than a 5% stake in Patrys Limited (PAB). However, you won't necessarily see their names in the company’s annual report, as many trade under nominee names. These shareholders are obliged to provide ongoing substantial notices relating to any change of 1% or more.

Holding Name
250,000,000 (5.45%) Mr Anton Uvarov

PAB Calendar of Events

Date Event
25 February 2027 Report (Interim)
04 September 2026 Report (Annual)
28 August 2026 Report (Prelim)

DISCLOSURE: InvestSMART Group Limited employees may have an interest in the securities and managed funds displayed via this service. Please refer to our Financial Services Guide for more information.

Data shown on this website is sourced by Morningstar
© Morningstar. All rights reserved. Neither any Morningstar company nor any of their content providers guarantee the data or content contained herein to be accurate, complete or timely nor will they have any liability for its use or distribution. Any general advice has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Limited, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. You should consider the advice in light of these matters and, if applicable, the relevant Product Disclosure Statement (in respect of Australian products) or Investment Statement (in respect of New Zealand products) before making any decision to invest. No Morningstar-affiliated company or any of their employees is providing you with personalised financial advice. To obtain advice tailored to your particular circumstances, please contact a professional financial adviser. Some material is copyright and published under licence from ASX Operations Pty Limited ACN 004 523 782 ("ASXO"). Data and content is provided for personal use only.